The European Medicines Agency confirms that Intervacc’s application for the granting of a Community marketing authorization for Strangvac is complete and correctly submitted
Stockholm March 18, 2020 - Intervacc AB (publ) announces that the European Medicines Agency, EMA, has today confirmed that the company's application for the granting of a Community marketing authorization for Strangvac is complete and correctly submitted. The regulatory review process for the vaccine against equine strangles, a highly contagious infectious disease now can be initiated. Today, in accordance with the applicable timetable for the application process, EMA has confirmed that the application for the granting of a Community marketing authorization for Strangvac submitted by